{"id":"https://genegraph.clinicalgenome.org/r/0377da3f-d414-4160-b2bd-472d3333843dv1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/0377da3f-d414-4160-b2bd-472d3333843d","GCISnapshot":"https://genegraph.clinicalgenome.org/r/dad38816-be17-4d59-bbfd-3e79221911a4","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/dad38816-be17-4d59-bbfd-3e79221911a4_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/dad38816-be17-4d59-bbfd-3e79221911a4_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2018-10-09T16:00:00.000Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dad38816-be17-4d59-bbfd-3e79221911a4_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a9d89a9-860a-41cd-86e9-75252bf90cb8_proband_score_evidence_line","type":"EvidenceLine","dc:description":"ECHS1 activity and protein absent from patient fibroblasts.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6a4409b-6680-4a53-8ed5-0f227ab3fc38","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25125611","rdfs:label":"Peters 2014 Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"Sequencing of ECHS1.","phenotypeFreeText":"CSF lactate was 4.9 mM (reference range <3.0), pyruvate was 0.32 mM (0.06–0.13) with a normal CSF lactate to pyruvate ratio. Serum lactate ranged 2.8 to 4.7 mM (0.5–2.0).","phenotypes":["obo:HP_0011968","obo:HP_0012762","obo:HP_0001273","obo:HP_0008947","obo:HP_0002104","obo:HP_0002878","obo:HP_0007366","obo:HP_0001662"],"previousTesting":true,"previousTestingDescription":"Semiquantitative urine metabolite screening by tandem mass spectrometry showed increased levels of S-(2-carboxypropyl)cysteine.  Urine organic acid screening by gas chromatography-mass spectrometry also showed increased levels of 2-methyl-2,3-dihydroxybutyrate. Negative for mutations in HIBCH. Normal urine excretion of 3-hydroxyisobutyryl-carnitine","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/9a9d89a9-860a-41cd-86e9-75252bf90cb8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25125611","allele":[{"id":"https://genegraph.clinicalgenome.org/r/6d630365-0ae0-4ca3-9b84-a809958480a2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.414+3G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/187860"}},{"id":"https://genegraph.clinicalgenome.org/r/cd7da7f4-fba0-430d-aad8-19ce95af896e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.473C>A (p.Ala158Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/187859"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/272626e4-d89c-443c-9943-bd6eafb8871f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"2-enoyl-CoA hydratase activity in the fibroblasts was significantly reduced along with ECHS1 protein.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9fe3e849-5d77-413b-b802-39a7d84124e1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"Patient 42031","ageType":"AgeAtOnset","ageUnit":"Days","detectionMethod":"Targeted enrichment of 1476 nuclear genes (including 1013 genes coding for mitochondrial proteins) followed by Sanger sequencing in family.","phenotypeFreeText":"2-methyl-2,3-dihydroxybutyrate 229-fold; reduced pyruvate dehydrogenase in fibroblasts;","phenotypes":["obo:HP_0000648","obo:HP_0001263","obo:HP_0000365","obo:HP_0001332","obo:HP_0003236","obo:HP_0001250","obo:HP_0001712","obo:HP_0001639","obo:HP_0006976","obo:HP_0002179","obo:HP_0003128"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/272626e4-d89c-443c-9943-bd6eafb8871f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":[{"id":"https://genegraph.clinicalgenome.org/r/00f28253-46a7-418a-a80f-4b7f09541c0f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.449A>G (p.Asp150Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378820752"}},{"id":"https://genegraph.clinicalgenome.org/r/f49d9a2d-db9c-4090-a889-65f6c374600b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.197T>C (p.Ile66Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA216819172"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4507e985-1d67-4ced-b44b-21b34194318a_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/399069e2-c7a7-4365-93bf-4d1d90e20bec","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"Patient 57277","ageType":"AgeAtOnset","ageUnit":"Days","detectionMethod":"","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"IncreasedT2-signal intensity in putamen and globus pallidus","phenotypes":["obo:HP_0001332","obo:HP_0001263","obo:HP_0003128","obo:HP_0002151","obo:HP_0012043","obo:HP_0000648","obo:HP_0002015","obo:HP_0000365"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/4507e985-1d67-4ced-b44b-21b34194318a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":[{"id":"https://genegraph.clinicalgenome.org/r/5e857fe3-ad49-4035-937c-d2c2e7c0f716","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.431dup (p.Leu145AlafsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820931"}},{"id":"https://genegraph.clinicalgenome.org/r/495945de-c01d-48ec-9366-c1de02088c4d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.161G>A (p.Arg54His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5765861"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ae50181a-632f-4083-ab26-f5c328929755_proband_score_evidence_line","type":"EvidenceLine","dc:description":"ECHS1 activity was reduced to 2-6% 6.2% in patient cells compared to controls.  Protein was barely detectable on western blot. Transfection of WT ECHS1 in patient cells restored activity, but not expression of the variants.  In vitro functional expression studies showed that the D59S mutant was nonfunctional, whereas the A138V mutant had about 30% residual activity.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/78608df4-428b-46d7-b951-911a70afda48","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26251176","rdfs:label":"III-2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"detectionMethod":"Genome-wide SNP linkage analysis with 8 family members.  WES on 3 family members, followed by RFLP on the rest of the family members.","phenotypeFreeText":"MRI: bilateral hyperintensity was observed at the putamen, globus pallidus, caudate nucleus and substantia nigra. CS ratio in the respiratory chain within the normal limit; complex I 81%,\ncomplex II 104%, complex II+III 99%, complex III 95% and complex IV 93%. Urine organic acid analysis  showed elevated urine lactate: 22.6-73.07 (normal 0-4.7). N-Acetyl-S-(2-carboxypropyl)cysteine levels 3-4 times higher than normal.","phenotypes":["obo:HP_0002376","obo:HP_0001332"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ae50181a-632f-4083-ab26-f5c328929755_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26251176","allele":[{"id":"https://genegraph.clinicalgenome.org/r/9cbb4008-63bc-46fd-850a-dceee3820a6b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.413C>T (p.Ala138Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/218891"}},{"id":"https://genegraph.clinicalgenome.org/r/c02bc81d-c019-4a61-ad67-6d8e0f2364d0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.176A>G (p.Asn59Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/218890"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/a50ed95c-6e73-436b-9625-efa988ceec1d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Protein was undetectable in patient cells. ECHS1 activity was 13% of controls. Similar results were seen when expressing the variants in DLD-1 cells.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b89186d5-4157-458e-96cc-1c480f584879","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25393721","rdfs:label":"Sakai 2015 Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":2,"detectionMethod":"","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Plasma and CSF lactate elevated (20.2 and 25.3 mg/dl); elevated glyoxylate in urine; muscle biopsy showed normalized values for complexes I, III, and IV activity were decreased to 39%, 34%, and 64% of control values, respectively.","phenotypes":["obo:HP_0002305","obo:HP_0008610","obo:HP_0001252","obo:HP_0000639","obo:HP_0001257","obo:HP_0002376"],"previousTesting":true,"previousTestingDescription":"PCR and sequencing of mtDNA to identify mutations related to Leigh syndrome.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a50ed95c-6e73-436b-9625-efa988ceec1d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25393721","allele":[{"id":"https://genegraph.clinicalgenome.org/r/b80c5cce-dbfd-4a2c-94f9-56068916ebdd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.2T>G (p.Met1Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/156433"}},{"id":"https://genegraph.clinicalgenome.org/r/8275b14a-500e-454f-935f-656e1d9dca98","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.5C>T (p.Ala2Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/156434"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/64afa7b9-e8d4-4b0b-922c-d5f8312b473b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf5814f8-fd73-495e-9833-9385e964f626","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"Patient 68552","ageType":"AgeAtOnset","ageUnit":"Days","detectionMethod":"Exome sequencing in proband followed by Sanger sequencing in family.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001332","obo:HP_0002518","obo:HP_0000737","obo:HP_0001252","obo:HP_0002151","obo:HP_0007281","obo:HP_0040288","obo:HP_0011968","obo:HP_0001250"],"previousTesting":true,"previousTestingDescription":"Neonatal adrenoleukodystrophy, biotinidase deficiency, Krabbe disease, GM1 gangliosidosis and metachromatic leukodystrophy were excluded biochemically.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/64afa7b9-e8d4-4b0b-922c-d5f8312b473b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":{"id":"https://genegraph.clinicalgenome.org/r/f51bc10c-5679-4fd1-aa95-7dcc3d86b886","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.476A>G (p.Gln159Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/379794"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/d90534c7-018d-4087-a250-5c8fdb31635b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Parents were not tested so it's unclear if the variants are in cis or trans.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b6f7474-227a-42e7-a0ea-ad622b7948bd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"Patient 376","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":2,"detectionMethod":"","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Muscle biopsy showed mild deficiency of complex IV.","phenotypes":["obo:HP_0008947","obo:HP_0002151","obo:HP_0001263","obo:HP_0003128","obo:HP_0001250","obo:HP_0002134","obo:HP_0001644","obo:HP_0000365"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d90534c7-018d-4087-a250-5c8fdb31635b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":[{"id":"https://genegraph.clinicalgenome.org/r/c02bc81d-c019-4a61-ad67-6d8e0f2364d0"},{"id":"https://genegraph.clinicalgenome.org/r/b8258923-911d-40b8-9625-3796148ca18c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.98T>C (p.Phe33Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378823925"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/5dcd45ef-0313-4c1d-921b-6dd4e7ff1cf2_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8b70a951-a6a7-485a-a751-58103383c76b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"Patient 346","ageType":"AgeAtOnset","ageUnit":"Days","detectionMethod":"Exome sequencing in proband, Sanger sequencing in available family members.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Mild deficiency of complex I in liver.","phenotypes":["obo:HP_0004900","obo:HP_0007103","obo:HP_0002878","obo:HP_0012444","obo:HP_0001250","obo:HP_0000365","obo:HP_0001635","obo:HP_0001639"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5dcd45ef-0313-4c1d-921b-6dd4e7ff1cf2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":[{"id":"https://genegraph.clinicalgenome.org/r/f51bc10c-5679-4fd1-aa95-7dcc3d86b886"},{"id":"https://genegraph.clinicalgenome.org/r/c02bc81d-c019-4a61-ad67-6d8e0f2364d0"}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/4dc17443-b937-4e20-b61b-1f8b3ef90127_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e80aaab5-e80d-4139-b27e-dd6e0ee0b330","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"Patient 52236","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":11,"detectionMethod":"","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Signal hyperintensities in nucleus caudatus and putamen; mildly elevated lactate (2.5 mmol/L, normal<1.8 mmol/L) in CSF and inconsistently in serum (2.0–2.8 mmol/L,normal<2.2 mmol/L)","phenotypes":["obo:HP_0001263","obo:HP_0000666","obo:HP_0004322","obo:HP_0001250","obo:HP_0001332","obo:HP_0000365","obo:HP_0001288","obo:HP_0001260","obo:HP_0001285","obo:HP_0000648"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/4dc17443-b937-4e20-b61b-1f8b3ef90127_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":[{"id":"https://genegraph.clinicalgenome.org/r/4be60c03-ebd7-42a3-8a84-3d2f4876f01f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.229G>C (p.Glu77Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378822933"}},{"id":"https://genegraph.clinicalgenome.org/r/f51bc10c-5679-4fd1-aa95-7dcc3d86b886"}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/57859083-3db3-490e-afab-7a86d99d1297_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Parents were not tested so it's unclear if the variants are in cis or trans.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e54378e5-f66a-4304-a8ba-83a7f529271b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"Patient 68761","ageType":"AgeAtOnset","ageUnit":"Days","detectionMethod":"","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000252","obo:HP_0002521","obo:HP_0002500","obo:HP_0001250","obo:HP_0002650","obo:HP_0011968","obo:HP_0001263","obo:HP_0001298","obo:HP_0012444","obo:HP_0002015","obo:HP_0002340","obo:HP_0001332"],"previousTesting":true,"previousTestingDescription":"Normal citrate synthase- adjusted activities of respiratory chain complexes I-V but decreased overall ATP production. Pathogenic mutation of mitochondrial DNA excluded by Sanger sequencing of DNA from muscle.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/57859083-3db3-490e-afab-7a86d99d1297_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":[{"id":"https://genegraph.clinicalgenome.org/r/f51bc10c-5679-4fd1-aa95-7dcc3d86b886"},{"id":"https://genegraph.clinicalgenome.org/r/495945de-c01d-48ec-9366-c1de02088c4d"}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/215ace07-5fe5-47c5-a739-aecc44f8b347_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c5760d1-43a3-42dd-8371-c802c77f14eb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26081110","rdfs:label":"Patient 3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"detectionMethod":"WES, confirmed carrier status in parents with Sanger.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Gray matter atrophy, palms and face edematous, no voluntary movements; Elevated levels of blood lactate 3.9–7.2 mM (normal <2.2 mM) and of alanine 700 μM (normal <547 μM) ; increased urine lactate, Krebs cycle metabolites, 2-methyl-2,3-dihydroxybutyrate and 3-methylglutaconic acid; low pyruvate dehydrogenase activity.","phenotypes":["obo:HP_0000646","obo:HP_0005484","obo:HP_0000648","obo:HP_0002015","obo:HP_0002119","obo:HP_0002376","obo:HP_0002104","obo:HP_0001272","obo:HP_0000407","obo:HP_0007371","obo:HP_0008947","obo:HP_0007366"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/215ace07-5fe5-47c5-a739-aecc44f8b347_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26081110","allele":[{"id":"https://genegraph.clinicalgenome.org/r/20a30a8b-d6a0-4b53-b8b0-06a9bb29e5f1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.433C>T (p.Leu145Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378820871"}},{"id":"https://genegraph.clinicalgenome.org/r/f51bc10c-5679-4fd1-aa95-7dcc3d86b886"}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/65c3663e-9ea4-4ca9-89bf-3bc3590324cc_proband_score_evidence_line","type":"EvidenceLine","dc:description":"RT-PCR to test splicing showed a complete replacement of the normal transcript by an aberrant transcript that inserts 11 novel nucleotides and introduces a stop codon at amino acid 31. A 97% reduction in transcript was shown in affected individuals.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/34896b6d-d227-4c5a-8769-2e9c1d9b1d8c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27905109","rdfs:label":"Patient 1","ageType":"AgeAtOnset","ageUnit":"Days","detectionMethod":"Autozygosity mapping  using SNP Chip, followed by WES","phenotypeFreeText":"Lactic acid >20 mmol/L; elevated creatine phosphokinase 494, elevated plasma glycine 1779 (101–317 µmol/l) and alanine 2882 (108–448 umol/l), mildly elevated valine 272 (65–201 µmol/l), isoleucine 91 (22–82 µmol/l), and leucine 178 (47–175 µmol/l); mild elevation of butyrylcarnitine (C4), malonylcarnitine (C3DC), glutarylcarnitine (C5DC) and decanoylcarnitine (C10); cystic changes in caudothalamic grove and left periventricular and frontal white matter.","phenotypes":["obo:HP_0003161","obo:HP_0003236","obo:HP_0001518","obo:HP_0003648","obo:HP_0002643","obo:HP_0002154","obo:HP_0001942"],"previousTesting":true,"previousTestingDescription":"Targeted sequencing for candidate genes DLD, DLAT, PDHA1, PDHX, and PDHB was negative.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/65c3663e-9ea4-4ca9-89bf-3bc3590324cc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27905109","allele":{"id":"https://genegraph.clinicalgenome.org/r/fbaf8af3-c2b7-4bbd-8056-12d88f9d124f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.88+5G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/430372"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ffc372fe-6221-4fc9-8caa-04204b03b10f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06688d05-3e7d-4ef2-9157-e1769d5bb471","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"MRB166","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"detectionMethod":"Exome sequencing in proband followed by Sanger sequencing in family.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000218","obo:HP_0001543","obo:HP_0000278","obo:HP_0002151","obo:HP_0002078","obo:HP_0001263","obo:HP_0000365","obo:HP_0000300","obo:HP_0000455","obo:HP_0001252"],"previousTesting":true,"previousTestingDescription":"LPA PWS/AS, UBE3A, andMECP2 mutation analysis and microarray gave normal results.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ffc372fe-6221-4fc9-8caa-04204b03b10f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":[{"id":"https://genegraph.clinicalgenome.org/r/495945de-c01d-48ec-9366-c1de02088c4d"},{"id":"https://genegraph.clinicalgenome.org/r/b645d0de-a880-485f-b173-a1b04fb25b1f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.394G>A (p.Ala132Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/488499"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/39669e87-8959-4162-88f7-743191a85229_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Reduced ECHS1 activity and protein in fibroblasts.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/306ccb00-96dd-4fa5-a14c-dd9276da20d0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"Patient 73663","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":5,"detectionMethod":"","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Liquorisointense lesions in patuamen and palidum; 2-methyl-2,3-dihydroxybutyrate 39-fold; elevated lactate (8.5mmol/L), alanine (630umol/L), and ketone bodies; T2 signal abnormalities in periventricular white matter","phenotypes":["obo:HP_0001250","obo:HP_0002149","obo:HP_0001942","obo:HP_0003219","obo:HP_0001639","obo:HP_0007042","obo:HP_0002151","obo:HP_0012448","obo:HP_0001263","obo:HP_0001285","obo:HP_0006989"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/39669e87-8959-4162-88f7-743191a85229_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":{"id":"https://genegraph.clinicalgenome.org/r/22946e9e-7f0a-443b-b1d5-00e6d3d14e15","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.673T>C (p.Cys225Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5765684"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/95f8fd9a-62d3-402c-ad41-31dbb01d4f61_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/959b5fe8-c37d-43ba-99ac-437bf7a4353e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","rdfs:label":"Patient 76656","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"detectionMethod":"Exome sequencing in the proband followed by Sanger sequencing in the family.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Signal hyperintensities of putamen, globus pallidus, nucleus caudatus and periventricular white matter; 2-methyl-2,3-dihydroxybutyrate 6-fold; mild bilateral signal hyperintensities of putamen, globus pallidus, nucleus caudatus, and periventricular white matter.","phenotypes":["obo:HP_0000750","obo:HP_0000365","obo:HP_0002317","obo:HP_0001263","obo:HP_0001332","obo:HP_0001252","obo:HP_0002370","obo:HP_0001266"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/95f8fd9a-62d3-402c-ad41-31dbb01d4f61_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26000322","allele":[{"id":"https://genegraph.clinicalgenome.org/r/0923d388-b7f4-4526-995a-1190772624de","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.583G>A (p.Gly195Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5765722"}},{"id":"https://genegraph.clinicalgenome.org/r/15348953-50b6-4e09-bf64-e172fb5583f7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004092.3(ECHS1):c.268G>A (p.Gly90Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/426299"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":11.75},{"id":"https://genegraph.clinicalgenome.org/r/dad38816-be17-4d59-bbfd-3e79221911a4_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dad38816-be17-4d59-bbfd-3e79221911a4_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ade4766e-11c9-4779-ba6d-799fc5921ec0","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0cac3b6f-0805-4d24-b8d9-d26bcd4159da","type":"Finding","dc:description":"CS activity normalized values for complexes I, IV, and V activity in immortalized patient-derived myoblasts were decreased to 17%, 39%, and 43% of the controls. Transfection of ECHS1 restored activity (CS activity normalized values of complexes I, IV, and V were 3.5, 1.3, and 2.2 times higher than those in vector-only myoblasts).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25393721","rdfs:label":"Patient cell rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/dad38816-be17-4d59-bbfd-3e79221911a4_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3118cf05-7b04-4411-9fa9-9dee6a071d6a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2b874edb-d2d3-4971-91c2-dd0262b1c5ea","type":"Finding","dc:description":"Methacrylyl-CoA and acryloyl-CoA are highly reactive and are toxic to cells. A deficiency in ECHS1 would lead to a build up of these molecules, which can contribute to the neurodegeneration seen in patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25125611","rdfs:label":"Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/22558339-3e48-4f5b-b8ec-913a86b8b6b8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d0770ca4-0731-47f5-a417-44ace89c9f3b","type":"Finding","dc:description":"Northern blot analysis showed mRNA expression in the liver, fibroblasts, and muscle.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8012501","rdfs:label":"Liver Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2}],"evidenceStrength":"Definitive","sequence":262,"specifiedBy":"GeneValidityCriteria6","strengthScore":13.75,"subject":{"id":"https://genegraph.clinicalgenome.org/r/gbPh4g--1d8","type":"GeneValidityProposition","disease":"obo:MONDO_0014563","gene":"hgnc:3151","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_dad38816-be17-4d59-bbfd-3e79221911a4-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}